Neuraxis Inc (NRXS)

概要ニュース株価時系列ディスカッション予測

Relative Volume:

ネットキャッシュフロー:

Neuraxis Inc Stock (NRXS) Company Profile

Neuraxis Inc

Healthcare (1096)

Biotechnology (616)

(812) 689-0791

11550 North Meridian Street, Suite 325, Carmel

NRXS's Discussions on Twitter

Compare NRXS vs VRTX, REGN, ARGX, ALNY, RVMD

株式	価格	時価総額	収益	当期純利益	現金流量	EPS
NRXS Neuraxis Inc	7.14	88.42M	4.28M	-7.28M	-6.17M	-0.8146
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Neuraxis Inc (NRXS) 最新ニュース

Neuraxis Inc (NRXS) 財務データ

Neuraxis Inc (NRXS)

Neuraxis Inc Stock (NRXS) Company Profile

Compare NRXS vs VRTX, REGN, ARGX, ALNY, RVMD

Neuraxis Inc (NRXS) 最新ニュース

Neuraxis, Inc. Files Form 8-K with SEC: Company Details, Address, and Stock Listing on NYSE American - Minichart

NeurAxis Declares Q2 Stock Dividend on Series B - TipRanks

Neuraxis declares stock dividend for Series B preferred, ~80,463 common shares to be issued - TradingView

NRXSNeuraxis Inc Latest SEC Filings - Finviz

NeurAxis, Inc.(NYSEAM: NRXS) added to Russell Microcap Growth Benchmark Index - marketscreener.com

NeurAxis, Inc.(NYSEAM: NRXS) added to Russell 3000E Growth Benchmark - marketscreener.com

NeurAxis, Inc.(NYSEAM: NRXS) added to Russell Microcap Index - marketscreener.com

NeurAxis, Inc.(NYSEAM: NRXS) added to Russell 3000E Index - marketscreener.com

Price to sales forward of Neuraxis, Inc. – AMEX:NRXS - TradingView

Price to sales forward of Neuraxis, Inc. – BOATS:NRXS - TradingView

Enterprise value to EBIT forward of Neuraxis, Inc. – AMEX:NRXS - TradingView

Enterprise value to EBIT forward of Neuraxis, Inc. – BOATS:NRXS - TradingView

Price to book forward of Neuraxis, Inc. – AMEX:NRXS - TradingView

Enterprise value to revenue forward of Neuraxis, Inc. – AMEX:NRXS - TradingView

Price to earnings forward of Neuraxis, Inc. – BOATS:NRXS - TradingView

Enterprise value to EBITDA forward of Neuraxis, Inc. – BOATS:NRXS - TradingView

NRXS Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts Investor SentimentProfit Inflection Point - dars.gov.et

NeurAxis, Inc. Actuals & Estimates (AMEX:NRXS) - TradingView

NRXS Forecast — Price Target — Prediction for 2027 - TradingView

Neuraxis Inc (NRXS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Neuraxis Inc (NRXS) Valuation: PE, PB & Fair Value Analysis - TradingKey

Neuraxis Inc (NRXS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Neuraxis Inc (NRXS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Neuraxis Inc (NRXS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Neuraxis Inc (NRXS) Institutional Confidence - TradingKey

Neuraxis Inc (NRXS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Neuraxis Inc (NRXS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Neuraxis Inc (NRXS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Neuraxis Inc. (NRXS) Q1 2026 Earnings: Narrower Loss Surprises Market, Shares Drop 2.76%Balance Sheet Strength - dars.gov.et

NeurAxis Stockholders Approve Directors and Equity Compensation Plans - The Globe and Mail

Neuraxis elects board members and approves plan amendments at annual meeting - Investing.com

NRXS Q1 2026 Earnings: Smaller-than-Expected Loss Bolsters Investor SentimentShare Repurchase Impact - newsline.com

NRXS Q1 2026 Earnings: EPS Beats Estimates Amid Ongoing Development FocusGuidance Accuracy Score - newsline.com

NRXS Q1 2026 Earnings: EPS Beats Estimates but Stock Declines on Broader ConcernsRetail Earnings Report - dars.gov.et

NRXS Q1 2026 Earnings: EPS Beat Surprises as Pre-Revenue Biotech Tightens LossesEstimate Revision Count - The Legal Advocate

NRXS Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionForward EPS Estimate - thelegaladvocate.com

Neuraxis Inc. (NRXS) Slides 2.15% as Key Support Level TestedPCR Divergence - The Legal Advocate

NRXS: Record Q1 revenue and expanded coverage drive growth in pediatric and VA neuromodulation markets - TradingView

NRXS Q1 2026 Earnings: EPS Beats Estimates Despite Revenue AbsenceRevenue Warning Signal - The Legal Advocate

Neuraxis Inc. (NRXS) Q1 2026 Earnings: EPS Surpasses Estimates Amid Operational ProgressGAAP Earnings Report - The Legal Advocate

NRXS: Neuromodulation therapies for GI disorders drive growth with FDA clearance and strong clinical data - TradingView

Neuraxis Inc. (NRXS) Holds Near Support After Marginal DeclineMA Cross Alert - Newser

Neuraxis Inc. (NRXS) Q1 2026 Earnings: Narrower Loss Beats Estimates, but Stock Slips on Pre‑Revenue Concerns - Newser

NeurAxis Earnings Call Highlights Growth and Hurdles - The Globe and Mail

NeurAxis (NRXS) Gains on Reimbursement Updates and Guideline MomentumShare Dilution Risk - The Legal Advocate

Minot Light Capital Fund Drops 2.7 Percent Amid Sector Rotation - HarianBasis.co

NeurAxis (NRXS) Climbs on Reimbursement and Guideline Momentum - Insider Monkey

Neuraxis (NRXS) Stock Analysis: -5.84% Loss — Key Levels 2026-05-18Stock Idea Hub - Newser

NeurAxis slides 21%, raises $5M via stock - MSN

The surprise hidden in Neuraxis NRXS last earnings report Q4 2025 Earnings Beat EstimatesCrowd Verified Signals - Newser

NeurAxis Stock Gains Post Q1 Earnings, Revenues and Margin Surge Y/Y - Yahoo Finance

Neuraxis Inc (NRXS) 財務データ

収益

当期純利益

現金流量

EPS

NRXSに似た銘柄